Company Reata Pharmaceuticals, Inc. Börse Stuttgart
Equities
2R3
US75615P1030
Biotechnology & Medical Research
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
- EUR | -.--% | +0.63% | +373.53% |
2023 | Reata Pharmaceuticals, Inc. Announces Management Changes | CI |
2023 | Biogen Closes Reata Pharmaceuticals Acquisition | MT |
Business Summary
Managers
Managers | Title | Age | Since |
---|---|---|---|
J. Huff
CEO | Chief Executive Officer | 70 | 01/22/01 |
Director of Finance/CFO | 60 | 26/23/26 | |
John Hunter
IRC | Investor Relations Contact | - | - |
Mike Visnick
PRN | Corporate Officer/Principal | - | 01/07/01 |
Robin Kral
PRN | Corporate Officer/Principal | - | 01/04/01 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
J. Huff
CEO | Chief Executive Officer | 70 | 01/22/01 |
Director/Board Member | - | 26/23/26 | |
Michael Dambach
BRD | Director/Board Member | - | 26/23/26 |
Robin Kramer
BRD | Director/Board Member | - | 26/23/26 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 3 | 4,515,246 | 0 | 0 | 75.54 % |
Stock B | 1 | 33,331,586 | 28,588,243 ( 85.77 %) | 0 |
Company contact information
Sector
1st Jan change | Capi. | |
---|---|---|
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B | |
+77.64% | 8.87B |
- Stock Market
- Equities
- RETA Stock
- 2R3 Stock
- Company Reata Pharmaceuticals, Inc.